310 related articles for article (PubMed ID: 29151034)
21. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
[TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
23. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
Blazing MA; Giugliano RP; de Lemos JA; Cannon CP; Tonkin A; Ballantyne CM; Lewis BS; Musliner TA; Tershakovec AM; Lokhnygina Y; White JA; Reist C; McCagg A; Braunwald E
Am Heart J; 2016 Dec; 182():89-96. PubMed ID: 27914504
[TBL] [Abstract][Full Text] [Related]
24. Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
Fras Z; Mikhailidis DP
Curr Vasc Pharmacol; 2021; 19(5):451-468. PubMed ID: 32720602
[TBL] [Abstract][Full Text] [Related]
25. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
[TBL] [Abstract][Full Text] [Related]
26. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
Simon TG; Corey KE; Cannon CP; Blazing M; Park JG; O'Donoghue ML; Chung RT; Giugliano RP
Int J Cardiol; 2018 Nov; 270():245-252. PubMed ID: 29903515
[TBL] [Abstract][Full Text] [Related]
27. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Bonaca MP; Gutierrez JA; Cannon C; Giugliano R; Blazing M; Park JG; White J; Tershakovec A; Braunwald E
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):934-943. PubMed ID: 30396865
[TBL] [Abstract][Full Text] [Related]
28. Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Sekiguchi H; Mori F; Haruta S; Ishii Y; Murasaki S; Suzuki K; Yamauchi T; Ogawa H; Hagiwara N
J Am Heart Assoc; 2019 Aug; 8(16):e012953. PubMed ID: 31390907
[TBL] [Abstract][Full Text] [Related]
29. COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Japaridze L; Sadunishvili M; Megreladze I
Georgian Med News; 2016 Mar; (252):15-22. PubMed ID: 27119829
[TBL] [Abstract][Full Text] [Related]
30. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
31. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
32. The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
Japaridze L; Sadunishvili M
Kardiol Pol; 2017; 75(8):770-778. PubMed ID: 28553847
[TBL] [Abstract][Full Text] [Related]
33. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
34. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
35. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
Qamar A; Giugliano RP; Bohula EA; Park JG; Jarolim P; Murphy SA; Blazing MA; Califf RM; Cannon CP; Braunwald E; Morrow DA
J Am Coll Cardiol; 2019 Aug; 74(8):1057-1068. PubMed ID: 31439215
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
39. Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome.
Im J; Kawada-Watanabe E; Yamaguchi J; Arashi H; Otsuki H; Matsui Y; Sekiguchi H; Fujii S; Mori F; Ogawa H; Hagiwara N
Sci Rep; 2021 Apr; 11(1):7480. PubMed ID: 33820931
[TBL] [Abstract][Full Text] [Related]
40. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
